

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): JANUARY 19, 2006

ENZO BIOCHEM, INC.

(Exact Name of Registrant as Specified in Its Charter)

NEW YORK

(State or Other Jurisdiction of Incorporation)

001-09974

13-2866202

(Commission File Number)

(IRS Employer Identification No.)

60 EXECUTIVE BOULEVARD
FARMINGDALE, NEW YORK

11735

(Address of Principal Executive Offices)

(Zip Code)

(631) 755-5500

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (SEE General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 8.01. OTHER EVENTS.

On January 19, 2006, Enzo Biochem, Inc., a New York corporation (the "Company"), issued a press release announcing that it has been issued a patent covering processes for producing large quantities of therapeutic proteins or RNAs within living target cells. The press release issued by the Company announcing the foregoing is included as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference in its entirety into this Item 8.01.

On January 19, 2006, the Company also issued a press release announcing the election of three Class III directors at the Company's 2006 annual meeting of stockholders (the "Annual Meeting") held on such date. The three Class III directors, each elected to three year terms, include Elazar Rabbani, Ph.D., Chairman, Chief Executive Officer and founder of the Company; John B. Sias, former President and Chief Executive Officer of Chronicle Publishing Company; and Marcus A. Conant, MD, Clinical Professor at the University of California San Francisco. Mr. Sias and Dr. Conant have served on the Company's Board of Directors since 1982 and 2004, respectively. The press release also announced that at the Annual Meeting the Company's stockholders also approved the amendment and restatement of the Company's 2005 Equity Compensation Incentive Plan (the "2005 Plan") which permits, among other things, restricted stock unit awards and adds specific performance criteria that may be used to establish performance objectives for awards. The 2005 Plan also eliminates automatic annual option grants to non-employee directors. The press release issued by the Company announcing the foregoing is included as Exhibit 99.2 to this Current Report and is incorporated by reference in its entirety into this Item 8.01.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits.

Exhibit No. -----	Description -----
99.1	Press Release of Enzo Biochem, Inc., dated January 19, 2006, announcing patent award.
99.2	Press Release of Enzo Biochem, Inc., dated January 19, 2006, announcing results of Annual Meeting.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ENZO BIOCHEM, INC.

Date: January 19, 2006

By: /s/ Barry Weiner

Barry Weiner
President and Chief Financial Officer

EXHIBIT INDEX

Exhibit No. -----	Description -----
99.1	Press Release of Enzo Biochem, Inc., dated January 19, 2006, announcing patent award.
99.2	Press Release of Enzo Biochem, Inc., dated January 19, 2006, announcing results of Annual Meeting.

[ENZO LOGO]

NEWS
 RELEASE

 ENZO BIOCHEM, INC.
 527 MADISON AVENUE
 NEW YORK, NY 10022

FOR IMMEDIATE RELEASE

ENZO BIOCHEM AWARDED PATENT COVERING PROCESSES FOR PRODUCING
 THERAPEUTIC PROTEINS OR RNAS IN LIVING CELLS

FARMINGDALE, NY, January 19, 2006 - Enzo Biochem, Inc. (NYSE:ENZ), announced at its annual meeting today that it has been issued a patent covering processes for producing large quantities of therapeutic proteins or RNAs within living target cells.

The unusual property of this invention is that it relies upon signals and regulatory elements that do not otherwise exist within the cell. This may allow for a large yield of the specific molecule desired, either the protein or the nucleic acid. By not bringing recognizable signaling moieties into the cell, it could add an element of efficiency and safety to the process.

The patent, United States Patent No. 6,986,985 (the '985 patent) titled "Process for Producing Multiple Nucleic Acid Copies IN VIVO using a Protein Nucleic Acid Construct," was issued on January 17, 2006 by the United States Patent and Trademark Office.

An important application of this technology may be to deliver therapeutic proteins to particular target cells in animals and humans. It may also facilitate delivery of regulatory RNA molecules, including antisense RNA molecules for the management of medically important diseases. As such it could represent a potentially safer and a more efficient strategy for gene expression and protein production in mammals, including humans.

"This patent adds a further component to our Company's broad technical capabilities and intellectual property portfolio in the area of protein supplementation therapy," said Elazar Rabbani, Ph.D., Enzo's Chairman and Chief Executive Officer, "and is indicative of the broad value contained in our intellectual property, as demonstrated by our patent estate in excess of more than 200 worldwide patents."

ABOUT ENZO

Enzo Biochem is engaged in the research, development and manufacture of innovative health care products based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community. The Company's proprietary labeling and detection products for gene sequencing and genetic analysis are sold to the life sciences market throughout the world. The Company's therapeutic division is in various stages of clinical evaluation of its proprietary gene medicine for HIV-1 infection and its proprietary immune regulation medicines for hepatitis B and hepatitis C infection and for Crohn's Disease. Pre-clinical research is being conducted on several candidate compounds aimed at producing new mineral and organic bone, including technology that could provide therapy for osteoporosis and fractures, among other applications. The Company also holds a patent covering a method and materials for correcting point mutations or small insertions or deletions of genetic material that would allow for editing and correcting certain abnormalities in genes. The Company owns or licenses over 200 patents worldwide. For more information visit our website www.enzo.com.

- more -

Enzo Biochem, Inc. - Page 2

EXCEPT FOR HISTORICAL INFORMATION, THE MATTERS DISCUSSED IN THIS NEWS RELEASE MAY BE CONSIDERED "FORWARD-LOOKING" STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE SECURITIES ACT OF 1933, AS AMENDED AND SECTION 21E OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. SUCH STATEMENTS INCLUDE DECLARATIONS REGARDING THE INTENT, BELIEF OR CURRENT EXPECTATIONS OF THE COMPANY AND ITS MANAGEMENT. INVESTORS ARE CAUTIONED THAT ANY SUCH FORWARD-LOOKING STATEMENTS ARE NOT GUARANTEES OF FUTURE PERFORMANCE AND INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES THAT COULD MATERIALLY AFFECT ACTUAL RESULTS. THE COMPANY DISCLAIMS ANY OBLIGATIONS TO UPDATE ANY FORWARD-LOOKING STATEMENT AS A RESULT OF DEVELOPMENTS OCCURRING AFTER THE DATE OF THIS PRESS RELEASE.

#

CONTACT:

For: Enzo Biochem, Inc.

Steve Anreder, 212-532-3232 Or Ed Lewis, CEOcast, Inc., 212-732-4300

[ENZO LOGO]

NEWS
 RELEASE

 ENZO BIOCHEM, INC.
 527 MADISON AVENUE
 NEW YORK, NY 10022

FOR IMMEDIATE RELEASE

ENZO BIOCHEM SHAREHOLDERS ELECT
 THREE DIRECTORS AT ANNUAL MEETING

FARMINGDALE, NY, January 19, 2006 - Enzo Biochem, Inc. (NYSE:ENZ) announced the election of three directors at the Company's annual meeting today, as well as approval of the Company's 2005 Equity Compensation Incentive Plan.

The three Class III directors, each elected to three year terms, include Elazar Rabbani, Ph.D., Chairman, Chief Executive Officer and founder of Enzo; John B. Sias, former President and Chief Executive Officer of Chronicle Publishing Company; and Marcus A. Conant, MD, Clinical Professor at the University of California San Francisco. Mr. Sias and Dr. Conant have served on the Enzo Board since 1982 and 2004, respectively.

Shareholders approved the amendment and restatement of the 2005 Equity Compensation Incentive Plan which permits, among other things, restricted stock unit awards and adds specific performance criteria that may be used to establish performance objectives for awards. The plan also eliminates automatic annual option grants to non-employee directors.

The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending July 31, 2006, was also ratified at the meeting.

ABOUT ENZO

Enzo Biochem is engaged in the research, development and manufacture of innovative health care products based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community. The Company's proprietary labeling and detection products for gene sequencing and genetic analysis are sold to the life sciences market throughout the world. The Company's therapeutic division is in various stages of clinical evaluation of its proprietary gene medicine for HIV-1 infection and its proprietary immune regulation medicines for hepatitis B and hepatitis C infection and for Crohn's Disease. Pre-clinical research is being conducted on several candidate compounds aimed at producing new mineral and organic bone, including technology that could provide therapy for osteoporosis and fractures, among other applications. The Company also holds a patent covering a method and materials for correcting point mutations or small insertions or deletions of genetic material that would allow for editing and correcting certain abnormalities in genes. The Company owns or licenses over 200 patents worldwide. For more information visit our website www.enzo.com.

EXCEPT FOR HISTORICAL INFORMATION, THE MATTERS DISCUSSED IN THIS NEWS RELEASE MAY BE CONSIDERED "FORWARD-LOOKING" STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE SECURITIES ACT OF 1933, AS AMENDED AND SECTION 21E OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. SUCH STATEMENTS INCLUDE DECLARATIONS REGARDING THE INTENT, BELIEF OR CURRENT EXPECTATIONS OF THE COMPANY AND ITS MANAGEMENT. INVESTORS ARE CAUTIONED THAT ANY SUCH FORWARD-LOOKING STATEMENTS ARE NOT GUARANTEES OF FUTURE PERFORMANCE AND INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES THAT COULD MATERIALLY AFFECT ACTUAL RESULTS. THE COMPANY DISCLAIMS ANY OBLIGATIONS TO UPDATE ANY FORWARD-LOOKING STATEMENT AS A RESULT OF DEVELOPMENTS OCCURRING AFTER THE DATE OF THIS PRESS RELEASE.

###

CONTACT:

For: Enzo Biochem, Inc.
 Steve Anreder, 212-532-3232 Or Ed Lewis, CEOcast, Inc., 212-732-4300